Rylaze

(Asparaginase erwinia chrysanthemi (recombinant)-rywn)

Rylaze

Drug updated on 1/4/2024

Dosage FormInjection (intramuscular; 10 mg/0.5 mL)
Drug ClassAsparagine specific enzyme
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.

Product Monograph / Prescribing Information

Document TitleYearSource
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Prescribing Information.2022Jazz Pharmaceuticals Inc., Palo Alto, CA

Randomized Controlled Trials

Document TitleSex DistributionYearSource
Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study.
167Subjects
F: 38%
M: 62%
2023Blood: American Society of Hematology

Sex Distribution:

F:38%
M:62%
167Subjects

Year:

2023

Source:Blood: American Society of Hematology